BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Price Performance

Shares of BLRX opened at $3.49 on Tuesday. BioLineRx has a 12-month low of $3.24 and a 12-month high of $57.60. The business has a 50-day simple moving average of $7.10 and a two-hundred day simple moving average of $17.45. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The stock has a market cap of $6.98 million, a PE ratio of -0.40 and a beta of 1.41.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($2.80) earnings per share for the quarter, beating the consensus estimate of ($3.20) by $0.40. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. Analysts anticipate that BioLineRx will post -5.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc increased its holdings in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the period. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 at the end of the most recent quarter. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.